Capturing non Amplified Tumor Circulating DNA with Ultrasound Hydrodynamics
The project suggests replacing the labor-intensive, occasionally biased and costly PCR method currently used for the detection of genetic markers with a simple, non-PCR based DNA quantification method. The suggested system will ex...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RBCE-GENODIAGNOSENS
Recuring breast cancer early genetic diagnostic on a chip
159K€
Cerrado
ABODYFORCE
High Throughput Microfluidic Cell and Nanoparticle Handling...
2M€
Cerrado
BIOMEDMICROFLUIDICS
Modelling and Optimization of Microfluidic Devices for Biome...
100K€
Cerrado
TEC2012-34280
INTEGRACION LAB-ON-A-CHIP DE DISPOSITIVOS BIOFOTONICOS PARA...
138K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The project suggests replacing the labor-intensive, occasionally biased and costly PCR method currently used for the detection of genetic markers with a simple, non-PCR based DNA quantification method. The suggested system will exploit the ability of acoustic waves to probe the hydrodynamic shape of surface-bound molecules, rather than mass. The scientific challenge to be addressed is to push the limit of detection to the zM range obviating the need to use a polymerase for DNA amplification. The technological challenge is to fabricate ultra sensitive acoustic devices and after capturing with high efficiency very low numbers of DNA present in a complex medium detecting them on the device surface. These ambitious goals will be achieved by developing novel probes and nanoparticles of tailor-made sizes and shapes for enhanced acoustic response; exploiting high frequency acoustic devices up to the GHz range; and, employing magnetic beads with microfluidics for specific target-capturing and enrichment. The proof-of-principle will be demonstrated during the detection of circulating-tumor DNA (ctDNA), currently an area perceived by cancer researchers as the Holy Grail of future cancer diagnosis, prognosis and treatment. We intend to validate our integrated acoustic platform towards the detection of common mutations occurring in colorectal and lung cancers, i.e., KRAS, EGFR and BRAF in serum. We anticipate that the CATCH-U-DNA concept will set the foundations for a simpler, more sensitive and affordable diagnostic method, from which patients in both the developed and developing countries will greatly benefit.